← Human Trials & Peer-Reviewed Studies
Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients
Plain-language guide to PMID 10206720 (1999): double-blind randomized controlled trial study of VIP (Vasoactive Intestinal Peptide) in 14 subjects, eczema.
Key Facts
- PMID
- 10206720
- Journal
- Experimental dermatology
- Year
- 1999
- Study type
- Randomized Controlled Trial
- Authors
- Rukwied R et al. (2 authors)
- DOI
- 10.1111/j.1600-0625.1999.tb00346.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied VIP (Vasoactive Intestinal Peptide) in the context of eczema in this randomized controlled trial publication.
Responses to acetylcholine (ACh) and vasoactive intestinal polypeptide (VIP) were investigated in atopic eczema (AE) patients.
To elucidate the involvement of histamine to ACh-provoked vasoreactions and sensations, the researchers applied a selective H1-antagonist (cetirizine) 3 h prior to the ACh-administration.
Who Took Part
The abstract describes 14 subjects taking part.
PubMed indexes the participants as adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and crossover study.
Because people in this VIP (Vasoactive Intestinal Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the subjects and researchers unaware of who received VIP (Vasoactive Intestinal Peptide).
In the crossover set-up each of the subjects took both VIP (Vasoactive Intestinal Peptide) and the comparison in turn, acting as their own control.
What Was Measured
Responses to acetylcholine (ACh) and vasoactive intestinal polypeptide (VIP) were investigated in atopic eczema (AE) patients.
Solutions of acetylcholine (ACh, 0.55 M) and vasoactive intestinal polypeptide (VIP, 1.5x 10(-5) M) were injected (10 microl) intracutaneously into the volar forearm of 14 healthy subjects and 14 atopic eczema (AE) patients.
The subject headings attached to it are Acetylcholine, Cetirizine, Cholinergic Agents, Dermatitis, Atopic, Erythema, Histamine H1 Antagonists and Injections, Intradermal.
What This Means in Plain Language
The paper is a randomized, double-blind and crossover study of VIP (Vasoactive Intestinal Peptide) in 14 subjects in people with eczema.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1999 (Experimental dermatology), a journal based in Denmark.
More context: the VIP (Vasoactive Intestinal Peptide) compound page, Eczema research.
Our Notes on the Compound
VIP (Vasoactive Intestinal Peptide): A 28-amino-acid neuropeptide that relaxes smooth muscle and calms immune activity; aviptadil is a synthetic form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.